Dishman Carbogen Amcis Ltd Hits Intraday High with 7.46% Surge on 9 Feb 2026

Intraday Trading Highlights

On 9 Feb 2026, Dishman Carbogen Amcis Ltd demonstrated strong buying momentum, with the stock touching a peak of Rs 216 during the trading session. This represents a 7.46% gain compared to its previous closing price, substantially outperforming the Sensex, which rose by 0.53% on the same day. The stock’s intraday advance also exceeded the Pharmaceuticals & Biotechnology sector’s performance by 6.29%, underscoring its relative strength within its industry group.

The stock’s upward movement marks a break in its recent downtrend, as it reversed course following three consecutive sessions of losses. This shift in trading dynamics suggests renewed interest in the stock at current price levels, supported by intraday volume and price action.

Technical Positioning and Moving Averages

From a technical perspective, Dishman Carbogen Amcis Ltd’s price currently trades above its 5-day moving average, indicating short-term positive momentum. However, it remains below its 20-day, 50-day, 100-day, and 200-day moving averages, reflecting that the stock is still within a broader medium- to long-term downtrend. This positioning highlights a potential resistance zone ahead, where the stock may encounter selling pressure if it attempts to sustain gains.

Market Context and Broader Indices

The broader market environment on 9 Feb 2026 was characterised by a positive opening for the Sensex, which began the day at 84,177.51 points, up 597.11 points or 0.71%. Although the index retreated slightly to trade at 84,020.65 points by mid-session, it still maintained a gain of 0.53%. The Sensex is currently trading approximately 2.55% below its 52-week high of 86,159.02 points, reflecting a market that is near its peak levels for the year.

Notably, the Sensex has been on a three-week consecutive rise, accumulating a gain of 3.05% over this period. Mega-cap stocks have been the primary drivers of this rally, providing a stable foundation for the market’s upward trajectory. Despite the Sensex trading below its 50-day moving average, the 50-day average remains above the 200-day moving average, indicating a generally positive medium-term trend for the benchmark index.

Performance Comparison Over Various Timeframes

While Dishman Carbogen Amcis Ltd’s intraday surge was impressive, its performance over longer periods remains mixed. The stock has underperformed the Sensex across multiple time horizons:

• One week: Dishman Carbogen Amcis Ltd gained 0.28%, trailing the Sensex’s 2.88% rise.
• One month: The stock declined by 16.12%, contrasting with the Sensex’s modest 0.53% gain.
• Three months: A decrease of 13.41% versus the Sensex’s 0.97% increase.
• One year: The stock fell 12.55%, while the Sensex advanced 7.91%.
• Year-to-date: Dishman Carbogen Amcis Ltd is down 12.87%, compared to the Sensex’s 1.41% decline.

However, the stock has demonstrated strong long-term growth, outperforming the Sensex over three and five years with gains of 150.29% and 69.94% respectively, compared to the Sensex’s 38.18% and 63.69% returns. This contrast highlights the stock’s volatility and cyclical nature within the Pharmaceuticals & Biotechnology sector.

Mojo Score and Rating Update

Dishman Carbogen Amcis Ltd currently holds a Mojo Score of 17.0, categorised as a Strong Sell. This rating was upgraded from Sell on 12 Jan 2026, reflecting a deterioration in the stock’s overall quality and market sentiment. The company’s Market Cap Grade stands at 3, indicating a mid-tier market capitalisation relative to its peers. These metrics provide a quantitative assessment of the stock’s risk and reward profile within the Pharmaceuticals & Biotechnology sector.

Summary of Trading Action

Dishman Carbogen Amcis Ltd’s strong intraday performance on 9 Feb 2026 was driven by a combination of technical factors and broader market strength. The stock’s 7.46% gain and intraday high of Rs 216 represent a clear rebound after a short-term decline, supported by its position above the 5-day moving average. Despite this, the stock remains below key longer-term moving averages, suggesting that further gains may require sustained buying interest and positive catalysts.

The broader market’s positive tone, with the Sensex advancing 0.53% and nearing its 52-week high, provided a supportive backdrop for the stock’s rally. Mega-cap leadership in the market and a three-week consecutive rise in the benchmark index contributed to an environment conducive to selective stock gains within the Pharmaceuticals & Biotechnology sector.

Investors and market participants will likely monitor the stock’s ability to maintain momentum and test resistance levels defined by its 20-day and 50-day moving averages in the coming sessions.

Unlock special upgrade rates for a limited period. Start Saving Now →